NCT06962098

Efficacy and Safety Study of Isuzinaxib in Subjects With DKD

A Phase 2b Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Evaluate the Efficacy and Safety of Isuzinaxib in Subjects With Diabetic Kidney Disease

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 186 (estimated)
• Sponsor: Aptabio Therapeutics, Inc. · Individual
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, double-blinded, randomized, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PK, and efficacy of Isuzinaxib compared with placebo in subjects with DKD.

Conditions

• Diabetic Kidney Disease (DKD)

Interventions

Type	Name	Description
DRUG	Isuzinaxib	Oral dosing regimen once daily
DRUG	Placebo	Oral dosing regimen once daily

Timeline

• Start date: 2025-05-26
• Primary completion: 2027-06-30
• Completion: 2028-06-30
• First posted: 2025-05-08
• Last updated: 2025-07-18

Locations

20 sites across 1 country: South Korea